Suski et al. suggested that targeting a single component of the cell cycle might be an effective anticancer strategy and discussed the potential of inhibiting different proteins related to the cell cycle in cancer therapy: for example, the protein Cyclin D1 is highly expressed in a variety of cancers, including BC 30. This evidence concerns the gene CCND1 and cancer.